GlassScriptPhysician profile
Adam W Paddock
NPI 1992131973
$5,052.85
in general payments reported to CMS, 2019-2025
22 companies · $893 in 2025
The $893 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $814 · 2022: $1,184 · 2023: $981 · 2024: $1,181 · 2025: $893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,875 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,874.61 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,244.49 | 2021-2025 | |
| Janssen Biotech, INC. | $450.34 | 2021-2025 | Tremfya |
| Incyte Corporation | $402.15 | 2021-2024 | Opzelura |
| Sun Pharmaceutical Industries INC. | $366.72 | 2021-2025 | |
| Pfizer INC. | $318.67 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $302.57 | 2021-2025 | |
| Genzyme Corporation | $263.84 | 2021-2025 | |
| Amgen INC. | $256.72 | 2021-2024 | Otezla |
| Regeneron Healthcare Solutions, INC. | $250.58 | 2022-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $205.56 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $193.16 | 2021-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $176.26 | 2022-2024 | Sotyktu |
| Ucb, INC. | $144.98 | 2021-2025 | Bimzelx |
| Lilly USA, LLC | $144.62 | 2021-2024 | Taltz, Olumiant |
| Leo Pharma INC. | $71.47 | 2021-2025 | Anzupgo, Adbry |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $63.88 | 2023 | |
| Kyowa Kirin, INC. | $41.86 | 2021-2022 | |
| Organon LLC | $41.31 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $39.60 | 2021 | |
| Paratek Pharmaceuticals, INC. | $38.56 | 2022 | |
| Biofrontera INC. | $20.34 | 2025 | Ameluz |
| Botanix Sb INC | $15.17 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Paddock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.